More than 500,000 Americans die from cancer every year, and many of those people spend their final hours in the emergency department. More and more patients and their families turn to ED doctors to help make difficult decisions when it comes to end-of-life issues. Dr. Arthur Derse, director of medical and legal affairs and associate director of the Medical College of Wisconsin's Center for the Study of Bioethics and professor of bioethics and emergency medicine, joins host Dr. Shira Johnson to look at how doctors can help terminally ill patients and their loved ones when it comes to living wills, life support and pain management.
Cancer and End-of-Life Issues in the Emergency Department
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
More than 500,000 Americans die from cancer every year, and many of those people spend their final hours in the emergency department. More and more patients and their families turn to ED doctors to help make difficult decisions when it comes to end-of-life issues. Dr. Arthur Derse, director of medical and legal affairs and associate director of the Medical College of Wisconsin's Center for the Study of Bioethics and professor of bioethics and emergency medicine, joins host Dr. Shira Johnson to look at how doctors can help terminally ill patients and their loved ones when it comes to living wills, life support and pain management.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Innovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway
0.25 credits
<p>Innovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway</p>
CME/CE
Evolving Our View of the Coagulation Cascade and Stroke Management
0.25 credits
<p><span data-contrast="auto" xml:lang="EN-US">Evolving Our View of the Coagulation Cascade and Stroke Management</span><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'> </span></p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
CME/CE
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
0.50 credits
<p>Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
MinuteCE®
Clinical Conundrums in ARIA: 1. Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies
1.25 credits
<p>Clinical Conundrums in ARIA: Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies</p>
MinuteCE®
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
1.25 credits
<p>Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy</p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?